All News
Biosimilars Match Biologic Originators in Rheumatoid Arthritis
A systematic review and meta-analysis in JAMA Network Open has shown that biosimilars of adalimumab, infliximab, and etanercept were associated with clinically equivalent treatment effects compared with their reference biologics for the treatment of rheumatoid arthritis (RA).
Read Article
Time to Risk Stratify Methotrexate Lab Monitoring?
A longitudinal cohort analysis has developed a prognostic model that informs a risk stratified approach to monitoring blood tests during long term methotrexate (MTX) therapy.
Read Article
WATCH: JAKpot or JAKnot
Dr. Jack Cush, executive editor of RheumNow, reporting on abstract OP0219 from EULAR 2023 in Milan, Italy.
https://t.co/RSJX4hcMRU https://t.co/XYuOrSCxjf
Links:
Dr. John Cush RheumNow ( View Tweet)
EULAR 2023 recommendation for imaging in large vessel vasculitis
Diagnosis of large vessel vasculitis can be challenging, and imaging modalities help with not only the diagnosis but sometimes in assessing flares in the disease.
https://t.co/o8cpSOXNy4
@bella_mehta https://t.co/aCM3yzT32e
Links:
Dr. John Cush RheumNow ( View Tweet)
Report of 54 nonradiographic axial SpA pts w/ recurrent fever. Fever preceded SpA in all; age @ axSpA Dx 39.9 yrs, w/ Dx delay 9.3 yrs. Fevers 38-42°C, arthralgia 61%, myalgia 44%, arthritis 41%, GI 25%, Rash 22%. Best Rx to TNFi > IL1i, colchicine, DMARD https://t.co/muSYhZFXku https://t.co/1lUPCMyuCX
Links:
Dr. John Cush RheumNow ( View Tweet)
Karolinska SARA (secretory antibodies in RA) study of 132 RA pts found salivary IgA anti-RgpB Abs signif higher in RA than (p = 0.022), & were assoc w/ disease activity (p = 0.036), but not with periodontitis or serum IgG ACPA. https://t.co/4uul4b5Fhg https://t.co/R5WVCyjc3B
Links:
Dr. John Cush RheumNow ( View Tweet)
RheumNow Eular 2023 Daily Recap Series - Day1 & 2
RheumNow faculty and reporters provide a daily recap of conference content coverage.
https://t.co/GCDmZT5dyE https://t.co/tXV9qDmcEu
Links:
Dr. John Cush RheumNow ( View Tweet)
Should we be reassured of JAK safety with new data?
Dr. Janet Pope discusses abstracts OP0133 and OP0132 at EULAR 2023 in Milan, Italy.
https://t.co/Gf4puWXkLY https://t.co/kcnpfEpnTW
Links:
Dr. John Cush RheumNow ( View Tweet)
Still's Disease Abstracts at EULAR 2023
https://t.co/lb1QRcsa9G https://t.co/JIBszS7s7D
Links:
Dr. John Cush RheumNow ( View Tweet)
Watch: IRAEs, Targeted Therapies and Survival
Dr. Aurelie Najm discusses OP0270 presented at EULAR 2023 in Milan, Italy.
@AurelieRheumo
https://t.co/501Rc4SPY1 https://t.co/Ifw93ICqwW
Links:
Dr. John Cush RheumNow ( View Tweet)
Novel drug in development, LY3361237, is a BTLA (B & T lymphocyte attenuator) agonistic antibody to treat autoimmune Dz (eg SLE) - augments immune responses by activating checkpoint inhibitory receptors (CIRs). https://t.co/3iYq9UwHww https://t.co/RwrhqRO8cm https://t.co/tl8qVIXqjc
Dr. John Cush RheumNow ( View Tweet)
Bimekizumab (Bimzelx) has been EMA approved to treat adults with active PsA & axial spondylarthritis in the EU. This dual IL-17 A/F inhibitor is approved to treat moderate -severe plaque psoriasis in the EU, Canada, UK & Japan; but not yet in USA https://t.co/kmjo3HYg4K https://t.co/PINZryXQBP
Links:
Dr. John Cush RheumNow ( View Tweet)
Swedish registry study shows of 3629 children born to mothers with RA#, 70 (1.94%) were diagnosed with Autism Spectrum disorder (ASD). If RA was dx before delivery, an increased risk of ASD (HR = 1.43), especially for seronegative RA (HR = 1.61) https://t.co/6OVZhkTdGc https://t.co/3VHhI7nfQm
Links:
Dr. John Cush RheumNow ( View Tweet)
Assessing CV Risk in Inflammatory Arthritis: Which Score?
Dr. Aurelie Najm discusses OP0267 presented at EULAR 2023 in Milan, Italy. @AurelieRheumo
https://t.co/qlJ9iMwrip
@AurelieRheumo https://t.co/Yh2siy6555
Links:
Dr. John Cush RheumNow ( View Tweet)
Abatacept: is there a role before RA hits?
Dr. David Liew discusses OP0130 at EULAR 2023 in Milan, Italy. @drdavidliew
https://t.co/SPLOCjjhUt https://t.co/wkPJLz9ctg
Links:
Dr. John Cush RheumNow ( View Tweet)
ANCA-associated vasculitis: beyond therapy with rituximab?
AAV is a group of multi-system autoimmune small vessel vasculitides which includes GPA, MPA and EGPA.
https://t.co/eZ3mgdjrEp https://t.co/dM9B4tVgmr
Links:
Dr. John Cush RheumNow ( View Tweet)
Methotrexate - an old trusted friend who deserves better
MTX has been used as the anchor drug for the treatment of RA and PsA for many years. It has been co-prescribed with biologics and JAKi in clinical trials and as well as in clinical practice.
https://t.co/xp40KklMkA https://t.co/oVqzlQeqbe
Links:
Dr. John Cush RheumNow ( View Tweet)
RheumNow Eular2023 Coverage - SLE Panel Discussion https://t.co/pLWOqZo2aw https://t.co/itAOjgmMTl
Links:
Dr. John Cush RheumNow ( View Tweet)
AOSD: Young vs. Elderly Onset
AOSDis an autoinflammatory condition characterized by fevers, arthritis, and rash. It is considered an orphan disease because of its low prevalence - it is reported anywhere between 16 to 40 per ten million.
https://t.co/fg5TakEvvv https://t.co/lu34gX7WTZ
Links:
Dr. John Cush RheumNow ( View Tweet)
EULAR 2023 Notes from Milan
Dr. Jack Cush reviews highlight abstracts and sessions - covering lupus, RA, gout, Still's disease, safety data, AI in medicine and more - from last week's EULAR 2023 Congress held in Milan, Italy
https://t.co/brcgGv2GHD https://t.co/zVyZkEuLy4
Links:
Dr. John Cush RheumNow ( View Tweet)
